{"id":5846,"date":"2024-10-21T15:48:25","date_gmt":"2024-10-21T20:48:25","guid":{"rendered":"https:\/\/nanostherapeutics.com\/?p=5846"},"modified":"2025-06-27T08:34:07","modified_gmt":"2025-06-27T13:34:07","slug":"nanoscope-publishes-breakthrough-showing-mco-010-treatment-arrests-neurodegeneration","status":"publish","type":"post","link":"https:\/\/nanostherapeutics.com\/es\/2024\/10\/21\/nanoscope-publishes-breakthrough-showing-mco-010-treatment-arrests-neurodegeneration\/","title":{"rendered":"Nanoscope publica un avance que demuestra que el tratamiento con MCO-010 detiene la neurodegeneraci\u00f3n"},"content":{"rendered":"
\n
\n
\n
\n

<\/h1>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n
\n
\n
\n
\n

DALLAS<\/span><\/span>,\u00a021 de octubre de 2024<\/span><\/span>\u00a0 \u2014 Nanoscopio Therapeutics Inc.<\/a>, una empresa de biotecnolog\u00eda cl\u00ednica en etapa avanzada que desarrolla terapias gen\u00e9ticas para enfermedades degenerativas de la retina, anunci\u00f3 hoy un\u00a0Descubrimiento revolucionario en la ciencia y tecnolog\u00eda de la visi\u00f3n traslacional.<\/a>\u00a0(TVST, una revista de ARVO) que demuestra que el tratamiento optogen\u00e9tico MCO-010 de la retina interna detiene una mayor degeneraci\u00f3n retiniana en un modelo animal de retinitis pigmentosa (RP), seg\u00fan se evalu\u00f3 mediante tomograf\u00eda de coherencia \u00f3ptica y an\u00e1lisis inmunohistoqu\u00edmico.<\/p>\n

Tras el tratamiento intrav\u00edtreo con MCO-010 (sonpiretigene isteparvovec<\/i>), se transdujeron aproximadamente 80% de c\u00e9lulas bipolares en la retina y no se observaron alteraciones en el espesor de la retina, a diferencia del grupo de control. Los resultados descritos en la publicaci\u00f3n proporcionan evidencia de que la expresi\u00f3n de MCO-010 en las retinas de ratones que experimentan degeneraci\u00f3n de fotorreceptores detiene una mayor p\u00e9rdida y previene una mayor desorganizaci\u00f3n de las capas de c\u00e9lulas de la retina.<\/p>\n

\u201cMCO-010 es la \u00fanica opsina de banda ancha, r\u00e1pida y altamente sensible que se encuentra actualmente en ensayos cl\u00ednicos y ha demostrado una mejora significativa en la visi\u00f3n en pacientes con retinosis pigmentaria avanzada. Adem\u00e1s de restaurar la visi\u00f3n mediante la inyecci\u00f3n intrav\u00edtrea de MCO-010, medida mediante ensayos conductuales y electrofisiol\u00f3gicos, este aspecto modificador de la enfermedad de MCO-010 proporciona una ventaja terap\u00e9utica clave en las terapias optogen\u00e9ticas al dirigirse a las c\u00e9lulas bipolares en la retina interna\u201d, dijo el Dr.\u00a0Vinit Mahajan<\/span>, Profesor y Vicepresidente de Investigaci\u00f3n, Departamento de Oftalmolog\u00eda de\u00a0Universidad Stanford<\/span>.<\/p>\n

\u201cEste aspecto modificador de la enfermedad del MCO-010 tambi\u00e9n se ha observado en un modelo animal de la enfermedad de Stargardt, as\u00ed como en el modelo de primates no humanos para la atrofia geogr\u00e1fica\u201d, dijo.\u00a0Samarendra Mohanty<\/span>, Ph.D., Presidente y Director Cient\u00edfico de Nanoscope. \u201cTenemos evidencia preliminar de estabilizaci\u00f3n de la estructura de la retina en el ensayo cl\u00ednico de retinosis pigmentaria, y planeamos realizar una evaluaci\u00f3n a largo plazo de este biomarcador anat\u00f3mico\u201d.\u201d<\/p>\n

Acerca de Nanoscope Therapeutics, Inc.
<\/b>Nanoscope Therapeutics est\u00e1 desarrollando terapias optogen\u00e9ticas que restauran la visi\u00f3n y que no dependen de los genes para los millones de pacientes que han perdido la visi\u00f3n a causa de enfermedades degenerativas de la retina, para las que no existe cura. Tras los resultados positivos de final de estudio del ensayo cl\u00ednico RESTORE de fase 2b, multic\u00e9ntrico, aleatorizado, doble ciego y controlado con placebo para la RP (NCT04945772<\/a>), la empresa\u00a0anunci\u00f3 su plan para iniciar la presentaci\u00f3n de BLA<\/a>\u00a0para MCO-010 para tratar la RP en el primer trimestre de 2025. MCO010 ha recibido designaciones de v\u00eda r\u00e1pida de la FDA y designaciones de medicamento hu\u00e9rfano de la FDA tanto para la RP como para Stargardt. La empresa ha completado el ensayo de fase 2 STARLIGHT de la terapia con MCO-010 en pacientes con Stargardt (NCT05417126<\/a>) y recientemente\u00a0anunci\u00f3 planes para iniciar una Fase 3<\/a>\u00a0ensayo de registro en el primer trimestre de 2025. Los activos precl\u00ednicos incluyen terapia g\u00e9nica MCO-020 administrada con l\u00e1ser no viral para la atrofia geogr\u00e1fica.<\/p>\n

Contacto de inversores:<\/b>
Socios Argot
(212) 600-1902
PR@nanostherapeutics.com<\/a><\/p>\n

FUENTE Terap\u00e9utica del Nanoscopio<\/p>\n<\/div>\n<\/div>\n<\/section>\n<\/article>","protected":false},"excerpt":{"rendered":"

DALLAS,\u00a0Oct. 21, 2024\u00a0 \u2014 Nanoscope Therapeutics Inc., a late-stage clinical biotechnology company developing gene therapies for retinal degenerative diseases today announced a\u00a0breakthrough discovery in Translational Vision Science & Technology\u00a0(TVST, an ARVO journal) demonstrating that MCO-010 optogenetic treatment of the inner retina arrests further retinal degeneration in an animal model of retinitis pigmentosa (RP), as assessed […]<\/p>\n","protected":false},"author":6,"featured_media":5847,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[13,8],"tags":[],"class_list":["post-5846","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-home-page","category-nanoscope-press-release"],"yoast_head":"\nNanoscope Publishes Breakthrough Showing MCO-010 Treatment Arrests Neurodegeneration - Nanoscope Therapeutics<\/title>\n<meta name=\"description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanostherapeutics.com\/es\/2024\/10\/21\/nanoscope-publishes-breakthrough-showing-mco-010-treatment-arrests-neurodegeneration\/\" \/>\n<meta property=\"og:locale\" content=\"es_MX\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanoscope Publishes Breakthrough Showing MCO-010 Treatment Arrests Neurodegeneration - Nanoscope Therapeutics\" \/>\n<meta property=\"og:description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanostherapeutics.com\/es\/2024\/10\/21\/nanoscope-publishes-breakthrough-showing-mco-010-treatment-arrests-neurodegeneration\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanoscope Therapeutics\" \/>\n<meta property=\"article:published_time\" content=\"2024-10-21T20:48:25+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-06-27T13:34:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/10\/NSCOPE_LI_TVSTPub_V1_REV.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"800\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Nanoscope Therapeutics\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/10\/NSCOPE_LI_TVSTPub_V1_REV.jpg\" \/>\n<meta name=\"twitter:creator\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:site\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Nanoscope Therapeutics\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/10\\\/21\\\/nanoscope-publishes-breakthrough-showing-mco-010-treatment-arrests-neurodegeneration\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/10\\\/21\\\/nanoscope-publishes-breakthrough-showing-mco-010-treatment-arrests-neurodegeneration\\\/\"},\"author\":{\"name\":\"Nanoscope Therapeutics\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\"},\"headline\":\"Nanoscope Publishes Breakthrough Showing MCO-010 Treatment Arrests Neurodegeneration\",\"datePublished\":\"2024-10-21T20:48:25+00:00\",\"dateModified\":\"2025-06-27T13:34:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/10\\\/21\\\/nanoscope-publishes-breakthrough-showing-mco-010-treatment-arrests-neurodegeneration\\\/\"},\"wordCount\":399,\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/10\\\/21\\\/nanoscope-publishes-breakthrough-showing-mco-010-treatment-arrests-neurodegeneration\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/NSCOPE_LI_TVSTPub_V1_REV.jpg\",\"articleSection\":[\"Home Page\",\"Nanoscope Press Release\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/10\\\/21\\\/nanoscope-publishes-breakthrough-showing-mco-010-treatment-arrests-neurodegeneration\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/10\\\/21\\\/nanoscope-publishes-breakthrough-showing-mco-010-treatment-arrests-neurodegeneration\\\/\",\"name\":\"Nanoscope Publishes Breakthrough Showing MCO-010 Treatment Arrests Neurodegeneration - Nanoscope Therapeutics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/10\\\/21\\\/nanoscope-publishes-breakthrough-showing-mco-010-treatment-arrests-neurodegeneration\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/10\\\/21\\\/nanoscope-publishes-breakthrough-showing-mco-010-treatment-arrests-neurodegeneration\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/NSCOPE_LI_TVSTPub_V1_REV.jpg\",\"datePublished\":\"2024-10-21T20:48:25+00:00\",\"dateModified\":\"2025-06-27T13:34:07+00:00\",\"description\":\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/10\\\/21\\\/nanoscope-publishes-breakthrough-showing-mco-010-treatment-arrests-neurodegeneration\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/10\\\/21\\\/nanoscope-publishes-breakthrough-showing-mco-010-treatment-arrests-neurodegeneration\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/10\\\/21\\\/nanoscope-publishes-breakthrough-showing-mco-010-treatment-arrests-neurodegeneration\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/NSCOPE_LI_TVSTPub_V1_REV.jpg\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/NSCOPE_LI_TVSTPub_V1_REV.jpg\",\"width\":1200,\"height\":800},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/10\\\/21\\\/nanoscope-publishes-breakthrough-showing-mco-010-treatment-arrests-neurodegeneration\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nanostherapeutics.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nanoscope Publishes Breakthrough Showing MCO-010 Treatment Arrests Neurodegeneration\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"name\":\"Nanoscope Therapeutics\",\"description\":\"Bringing Back the Light of Hope\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"alternateName\":\"Nanoscope Therapeutics\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanostherapeutics.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\",\"name\":\"Nanoscope Therapeutics, Inc\",\"alternateName\":\"Nanoscope Therapeutics\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"width\":512,\"height\":435,\"caption\":\"Nanoscope Therapeutics, Inc\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/NSTherapeutics\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/nanoscope\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\",\"name\":\"Nanoscope Therapeutics\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nanoscope publica un avance que demuestra que el tratamiento con MCO-010 detiene la neurodegeneraci\u00f3n - Nanoscope Therapeutics","description":"Nuestra plataforma de opsina multicaracter\u00edstica (MCO) es la primera en demostrar, en ensayos cl\u00ednicos, la capacidad de restaurar la visi\u00f3n en pacientes con enfermedades retinianas y p\u00e9rdida visual severa. Nanoscope ha desarrollado MCO-010, la primera y \u00fanica tecnolog\u00eda optogen\u00e9tica de amplio espectro, respuesta r\u00e1pida y ultrasensible para la restauraci\u00f3n de la visi\u00f3n, independiente del gen.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanostherapeutics.com\/es\/2024\/10\/21\/nanoscope-publishes-breakthrough-showing-mco-010-treatment-arrests-neurodegeneration\/","og_locale":"es_MX","og_type":"article","og_title":"Nanoscope Publishes Breakthrough Showing MCO-010 Treatment Arrests Neurodegeneration - Nanoscope Therapeutics","og_description":"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.","og_url":"https:\/\/nanostherapeutics.com\/es\/2024\/10\/21\/nanoscope-publishes-breakthrough-showing-mco-010-treatment-arrests-neurodegeneration\/","og_site_name":"Nanoscope Therapeutics","article_published_time":"2024-10-21T20:48:25+00:00","article_modified_time":"2025-06-27T13:34:07+00:00","og_image":[{"width":1200,"height":800,"url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/10\/NSCOPE_LI_TVSTPub_V1_REV.jpg","type":"image\/jpeg"}],"author":"Nanoscope Therapeutics","twitter_card":"summary_large_image","twitter_image":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/10\/NSCOPE_LI_TVSTPub_V1_REV.jpg","twitter_creator":"@NSTherapeutics","twitter_site":"@NSTherapeutics","twitter_misc":{"Escrito por":"Nanoscope Therapeutics","Tiempo de lectura":"2 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nanostherapeutics.com\/2024\/10\/21\/nanoscope-publishes-breakthrough-showing-mco-010-treatment-arrests-neurodegeneration\/#article","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/2024\/10\/21\/nanoscope-publishes-breakthrough-showing-mco-010-treatment-arrests-neurodegeneration\/"},"author":{"name":"Nanoscope Therapeutics","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2"},"headline":"Nanoscope Publishes Breakthrough Showing MCO-010 Treatment Arrests Neurodegeneration","datePublished":"2024-10-21T20:48:25+00:00","dateModified":"2025-06-27T13:34:07+00:00","mainEntityOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2024\/10\/21\/nanoscope-publishes-breakthrough-showing-mco-010-treatment-arrests-neurodegeneration\/"},"wordCount":399,"publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2024\/10\/21\/nanoscope-publishes-breakthrough-showing-mco-010-treatment-arrests-neurodegeneration\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/10\/NSCOPE_LI_TVSTPub_V1_REV.jpg","articleSection":["Home Page","Nanoscope Press Release"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/nanostherapeutics.com\/2024\/10\/21\/nanoscope-publishes-breakthrough-showing-mco-010-treatment-arrests-neurodegeneration\/","url":"https:\/\/nanostherapeutics.com\/2024\/10\/21\/nanoscope-publishes-breakthrough-showing-mco-010-treatment-arrests-neurodegeneration\/","name":"Nanoscope publica un avance que demuestra que el tratamiento con MCO-010 detiene la neurodegeneraci\u00f3n - Nanoscope Therapeutics","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2024\/10\/21\/nanoscope-publishes-breakthrough-showing-mco-010-treatment-arrests-neurodegeneration\/#primaryimage"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2024\/10\/21\/nanoscope-publishes-breakthrough-showing-mco-010-treatment-arrests-neurodegeneration\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/10\/NSCOPE_LI_TVSTPub_V1_REV.jpg","datePublished":"2024-10-21T20:48:25+00:00","dateModified":"2025-06-27T13:34:07+00:00","description":"Nuestra plataforma de opsina multicaracter\u00edstica (MCO) es la primera en demostrar, en ensayos cl\u00ednicos, la capacidad de restaurar la visi\u00f3n en pacientes con enfermedades retinianas y p\u00e9rdida visual severa. Nanoscope ha desarrollado MCO-010, la primera y \u00fanica tecnolog\u00eda optogen\u00e9tica de amplio espectro, respuesta r\u00e1pida y ultrasensible para la restauraci\u00f3n de la visi\u00f3n, independiente del gen.","breadcrumb":{"@id":"https:\/\/nanostherapeutics.com\/2024\/10\/21\/nanoscope-publishes-breakthrough-showing-mco-010-treatment-arrests-neurodegeneration\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanostherapeutics.com\/2024\/10\/21\/nanoscope-publishes-breakthrough-showing-mco-010-treatment-arrests-neurodegeneration\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nanostherapeutics.com\/2024\/10\/21\/nanoscope-publishes-breakthrough-showing-mco-010-treatment-arrests-neurodegeneration\/#primaryimage","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/10\/NSCOPE_LI_TVSTPub_V1_REV.jpg","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/10\/NSCOPE_LI_TVSTPub_V1_REV.jpg","width":1200,"height":800},{"@type":"BreadcrumbList","@id":"https:\/\/nanostherapeutics.com\/2024\/10\/21\/nanoscope-publishes-breakthrough-showing-mco-010-treatment-arrests-neurodegeneration\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nanostherapeutics.com\/"},{"@type":"ListItem","position":2,"name":"Nanoscope Publishes Breakthrough Showing MCO-010 Treatment Arrests Neurodegeneration"}]},{"@type":"WebSite","@id":"https:\/\/nanostherapeutics.com\/#website","url":"https:\/\/nanostherapeutics.com\/","name":"Terap\u00e9utica del nanoscopio","description":"Recuperando la luz de la esperanza","publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"alternateName":"Nanoscope Therapeutics","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanostherapeutics.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/nanostherapeutics.com\/#organization","name":"Nanoscope Therapeutics, Inc","alternateName":"Nanoscope Therapeutics","url":"https:\/\/nanostherapeutics.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","width":512,"height":435,"caption":"Nanoscope Therapeutics, Inc"},"image":{"@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/NSTherapeutics","https:\/\/www.linkedin.com\/company\/nanoscope"]},{"@type":"Person","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2","name":"Terap\u00e9utica del nanoscopio"}]}},"_links":{"self":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/5846","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/comments?post=5846"}],"version-history":[{"count":2,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/5846\/revisions"}],"predecessor-version":[{"id":9013,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/5846\/revisions\/9013"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/media\/5847"}],"wp:attachment":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/media?parent=5846"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/categories?post=5846"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/tags?post=5846"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}